Major players in the pressure ulcer treatment market include Phagelux, MiMedx, EyeGene, Shionogi Co., NovaLead Pharma, Smith Nephew PLC, Integra LifeSciences, Baxter International, Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen, ConvaTec Group, and Coloplast Group.

Overview of the bedsore treatment market

(Albany, USA) DelveInsight's report, "Pressure Ulcer Market Insights, Epidemiology, and Market Forecast - 2032," provides a comprehensive analysis of pressure ulcers, including historical and projected epidemiology, and market trends in the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan.

To strategically support companies developing pressure ulcer treatments, DelveInsight has released the report, "Epidemiology and Market Forecast for the Pressure Ulcer Market to 2032." This extensive report provides epidemiology-based market analysis and offers a roadmap for success in the evolving pressure ulcer market landscape.

Get a free sample of ".Bedsore market report」

Key highlights of the Pressure Ulcers Market Report:

• The pressure ulcer market is projected to grow at a significant CAGR during the study period of 7MM.
• Key companies in the pressure ulcer space include Phagelux, MiMedx, EyeGene, Shionogi Co., NovaLead Pharma, Smith Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, and Coloplast Group.
• Promising treatments for pressure ulcers include SR-0379, EGT 022, and GM-XANTHO.
• The incidence of pressure ulcers is significantly higher among people with diabetes.
• The prevalence of diabetes in the 7MM is estimated at 537 million adults, with approximately 150 million experiencing an ulcer at some point.
• Studies have shown that approximately 10% of individuals in the United States will experience an ulcer at some stage in their lives.
• The bedsore market is expected to expand due to the increasing prevalence of the condition and growing awareness during the forecast period. Furthermore, the introduction of various pipeline products is expected to significantly alter the dynamics of the bedsore market.

In October 2024, Imbed Biosciences announced FDA 510(k) clearance for Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing incorporating lidocaine for the management of painful skin wounds. This innovative dressing utilizes Imbed's patented synthetic matrix to deliver ionic and metallic silver along with lidocaine to provide both antimicrobial protection and local anesthetic benefits. It is indicated for a variety of partial and full thickness wounds under medical supervision, including venous stasis ulcers, pressure ulcers, ischemic ulcers, partial thickness burns, donor site wounds, surgical wounds, post-operative incisions, abrasions, and lacerations.

In July 2024, Xantho Biotechnology announced results from a Phase IIa study investigating the efficacy and safety profile of GM-XANTHO in patients with pressure ulcers.

Pressure Ulcer Treatment Analysis by Country:

The Pressure Ulcer Treatment Market report provides insights into treatment plans across the 7MM. The analysis helps companies understand the pressure ulcer treatment advancements taking place across these markets that have the potential to transform practice, patient journey, and treatment paradigms and improve patient outcomes.

Pressure sores, also known as bed sores or pressure ulcers, are localized damage to the skin and/or underlying tissue caused by prolonged pressure. They often occur in people who are bedridden, wheelchair bound, or have limited mobility, and usually form over bony prominences such as the heels, hips, tailbone, and elbows.

The development of pressure ulcers is influenced by several factors, including the pressure applied, duration, and the overall health of the individual. Reduced blood flow to the affected area can cause tissue damage, leading to pain, open wounds, and serious complications such as infection and tissue necrosis.

Prevention of pressure ulcers requires regular turning, maintaining proper nutrition, using special support surfaces, and good skin care. Early recognition and proper management are important to prevent progression and promote healing. Healthcare professionals provide individualized treatment including wound care, infection control, and pressure redistribution strategies to effectively manage pressure ulcers.

Download the report to understand what factors are driving pressure ulcer epidemiological trends.Epidemiological prediction of pressure ulcers

Epidemiological insights into pressure ulcers:

The report offers historical and projected epidemiological insights to help understand the patient population targeted by pressure ulcers. The analysis covers the period 2019 to 2032, providing insight into how patient trends will shape the market dynamics. Additionally, epidemiology is segmented to allow for detailed analysis of the patient pool, enabling companies to identify their target demographics. The report categorizes epidemiology as follows:

• Total prevalence of pressure ulcers
• Prevalent cases of pressure ulcers by severity
• Gender-specific prevalence of pressure ulcers
• Cases diagnosed as sudden and chronic pressure ulcers

Pressure Ulcer Market Companies and Therapies:

• EGT022:Developed by EyeGene, EGT 022 is a recombinant polypeptide containing an RGD motif derived from the human protein ADAM-15.

For more information on companies operating in the Pressure Ulcer Treatment market, please visit @Clinical trials and treatment evaluations for pressure ulcers

Uptake of emerging medications for pressure ulcers:

In October 2024, Imbed Biosciences announced FDA 510(k) clearance for Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing incorporating lidocaine for the management of painful skin wounds. The dressing utilizes Imbed's patented synthetic matrix to deliver ionic and metallic silver along with lidocaine to provide both antimicrobial protection and local anesthetic benefits. It is indicated for a variety of partial and full thickness wounds under medical supervision.

In July 2024, Xantho Biotechnology announced results from a Phase IIa study investigating the efficacy and safety profile of GM-XANTHO in patients with pressure ulcers.

In March 2021, Smith+Nephew reported results from a real-world study in Spain showing that switching to ALLEVYN LIFE foam dressings significantly reduced dressing change frequency and weekly dressing costs while improving clinician and patient satisfaction with treatment in the community.

In February 2021, Axis Biosolutions received European CE Mark approval for MAXiCel, an advanced wound care product used for a variety of chronic wounds, including pressure ulcers.

Find out more about the treatments expected to capture a major share in the pressure ulcer market @Bedsore Treatment Market

Pressure Ulcer Market Forecast:

The study includes a thorough analysis of the historical and projected market for pressure ulcers, including pharmacological prevalence, in 7MM countries. Pressure ulcer market trends are expected to evolve in the coming years owing to the expected launch of emerging treatments such as Thymosin β4, Ibuprofen, etc. during the forecast period 2019 to 2032. Despite rising prevalence, growing awareness, limited competition for upcoming treatments, and low awareness of pressure ulcers, companies shifting their focus to this area are driving the pressure ulcer market.

Coverage of the Pressure Ulcers Market Report:

• Geographic Coverage: 7MM
• Study period: 2019-2032
• Major companies:Phagelux, MiMedx, EyeGene, Shionogi Co., NovaLead Pharma, Smith Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, Coloplast Group, and others.

Request a sample report:https://www.delveinsight.com/sample-request/pressure-ulcers-market

DelveInsight's reports provide comprehensive insights, market analysis, and forecasts to help key businesses make strategic decisions within the pressure ulcers market landscape.

Gain a competitive edge in the pressure ulcer market:Understand the current situation, including the competitive landscape, key companies developing Pressure Ulcer Drugs, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can effectively position themselves and identify opportunities to gain competitive advantage.

Identify market gaps and opportunities:Analysing epidemiological trends, patient trajectories by country and existing treatments can help identify gaps and opportunities within the pressure ulcer market. Recognising areas where current treatments may be inadequate or where unmet needs exist can encourage stakeholders to explore new treatments, potentially leading to the development of new therapies to address specific market needs.

Strategic Decision-Making:Armed with insights from epidemiology and market forecasts, stakeholders can make informed strategic decisions regarding RD investments, portfolio expansion, pricing and reimbursement strategies, partnerships, and other strategic initiatives. Understanding market dynamics allows stakeholders to align their goals with prevailing trends and future projections.

Plan your roadmap to success:The report enables leading pressure ulcer companies to set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap will enable stakeholders to navigate the complexities of the pressure ulcer market with clarity and purpose.

About DelveInsight

DelveInsight is a prominent healthcare business consulting and market research firm focused on life sciences. We support pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance. Additionally, we also offer healthcare consulting services to facilitate market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Information

Kanishk

Email - kkumar@delveinsight.com